$8.61 Billion is the total value of Bellevue Group AG's 220 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AUPH | New | AURINIA PHARMACEUTICALS INC | $29,784,000 | – | 2,405,825 | +100.0% | 0.35% | – |
| CSTL | New | CASTLE BIOSCIENCES INC | $27,258,000 | – | 607,614 | +100.0% | 0.32% | – |
| DOCS | New | DOXIMITY INCcl a | $4,316,000 | – | 82,860 | +100.0% | 0.05% | – |
| CYTK | New | CYTOKINETICS INC | $2,540,000 | – | 69,000 | +100.0% | 0.03% | – |
| SNY | New | SANOFIsponsored adr | $2,238,000 | – | 43,600 | +100.0% | 0.03% | – |
| ABC | New | AMERISOURCEBERGEN CORP | $2,011,000 | – | 13,000 | +100.0% | 0.02% | – |
| ALKS | New | ALKERMES PLC | $1,973,000 | – | 75,000 | +100.0% | 0.02% | – |
| SUPN | New | SUPERNUS PHARMACEUTICALS INC | $1,907,000 | – | 59,000 | +100.0% | 0.02% | – |
| PCRX | New | PACIRA BIOSCIENCES INC | $1,613,000 | – | 21,136 | +100.0% | 0.02% | – |
| KURA | New | KURA ONCOLOGY INC | $1,061,000 | – | 65,980 | +100.0% | 0.01% | – |
| NVCR | New | NOVOCURE LTD | $704,000 | – | 8,500 | +100.0% | 0.01% | – |
| GDX | New | VANECK ETF TRUSTgold miners etf | $514,000 | – | 13,400 | +100.0% | 0.01% | – |
| RLMD | New | RELMADA THERAPEUTICS INC | $432,000 | – | 16,000 | +100.0% | 0.01% | – |
| GOOG | New | ALPHABET INCcap stk cl c | $377,000 | – | 135 | +100.0% | 0.00% | – |
| PDD | New | PINDUODUO INCsponsored ads | $19,000 | – | 466 | +100.0% | 0.00% | – |
| BILI | New | BILIBILI INCspons ads rep z | $19,000 | – | 744 | +100.0% | 0.00% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- BB Biotech AG #1
- Bellevue Asset Management AG #2
- Bellevue Asset Management (UK) Ltd. #3
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-05-13
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| IONIS PHARMACEUTICALS INC | 31 | Q3 2023 | 9.3% |
| Vertex Pharmaceuticals Incorporated | 31 | Q3 2023 | 5.9% |
| NEUROCRINE BIOSCIENCES INC | 31 | Q3 2023 | 5.7% |
| Incyte Corporation | 31 | Q3 2023 | 5.4% |
| INTUITIVE SURGICAL INC | 31 | Q3 2023 | 4.7% |
| ABBOTT LABS | 31 | Q3 2023 | 4.6% |
| ELEVANCE HEALTH INC | 31 | Q3 2023 | 4.3% |
| UnitedHealth Group Incorporated | 31 | Q3 2023 | 3.6% |
| ALNYLAM PHARMACEUTICALS INC | 31 | Q3 2023 | 3.7% |
| Boston Scientific Corporation | 31 | Q3 2023 | 2.5% |
View Bellevue Group AG's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| SC 13G | 2023-02-14 |
| SC 13G | 2023-02-14 |
| 13F-HR | 2022-11-14 |
View Bellevue Group AG's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.